Zobrazeno 1 - 10
of 357
pro vyhledávání: ''
Autor:
Rong Qiao, Shuyuan Wang, Bo Zhang, Jianlin Xu, Baohui Han, Yiming Zhao, Yanwei Zhang, Lele Zhang
Publikováno v:
Targeted Oncology. 14:169-178
Patients harboring concomitant epidermal growth factor receptor (EGFR) mutations and anaplastic lymphoma kinase (ALK) arrangements constitute a small subgroup of non-small-cell lung cancer (NSCLC) patients. The efficacy of EGFR tyrosine kinase inhibi
Autor:
Yujun Zhang, Ping Hu, Ping Gu, Changhui Li, Fang Hu, Shuyuan Wang, Jianlin Xu, Yinchen Shen, Bo Zhang, Huimin Wang, Xueyan Zhang, Wei Nie
Publikováno v:
Clinical Lung Cancer. 20:e81-e90
Background For oligometastatic lung adenocarcinoma patients with sensitive epidermal growth factor receptor (EGFR) mutations, the role of local consolidative therapy (LCT) remains debatable. The purpose of this study was to investigate the efficacy o
Autor:
Hiroki Nakahara, Kentaro Ito, Osamu Hataji, Atsushi Fujiwara, Esteban C. Gabazza, Corina N. D’Alessandro-Gabazza, Hajime Fujimoto, Osamu Taguchi, Taro Yasuma, Masamichi Yoshida, Tetsu Kobayashi, Kota Nishihama
Publikováno v:
Oncology Research
Tyrosine kinase inhibitors (TKIs) are very effective against non-small cell lung cancer (NSCLC) caused by epidermal growth factor receptor (EGFR) mutation. Before the approval of osimertinib in March 2016, there were only three available EGFR TKIs (g
Autor:
Shuhei Moriguchi, Atsushi Miyamoto, Sayaka Mochizuki, Kyoko Murase, Hisashi Takaya, Nasa Morokawa, Hironori Uruga, Kazumasa Ogawa, Shigeo Hanada, Kazuma Kishi, Yui Takahashi
Publikováno v:
BMC Cancer, Vol 18, Iss 1, Pp 1-4 (2018)
BMC Cancer
BMC Cancer
Background Pneumatosis intestinalis (PI) is a rare complication of chemotherapy, characterized by multiple gas accumulations within the bowel wall. Case presentation A 71-year-old woman with epidermal growth factor receptor (EGFR) mutation-positive l
Autor:
Satoshi Watanabe, Osamu Ishimoto, Ai Masumoto, Hirohisa Yoshizawa, Toshihiro Nukiwa, Yosuke Kawashima, Shunichi Sugawara, Ou Yamaguchi, Toshiaki Kikuchi, Yuri Maeno, Kunihiko Kobayashi
Publikováno v:
Anticancer Research. 38:4699-4704
Background/aim Promising reports have described the combination of first-generation epidermal growth factor receptor tyrosine-kinase inhibitors (EGFR-TKIs) with carboplatin plus pemetrexed or bevacizumab. However, no analysis of afatinib with platinu
Publikováno v:
Translational Lung Cancer Research. 7:S134-S137
Dacomitinib is a second-generation, irreversible EGFR tyrosine kinase inhibitor. We compared its efficacy and safety with that of the reversible EGFR tyrosine kinase inhibitor gefitinib in the first-line treatment of patients with advanced EGFR-mutat
Autor:
Shoji Fukushima, Nobuyuki Katakami, Shiro Fujita, Yasushi Yatabe, Katsuhiro Masago, Fumiko Imamichi, Kei Irie, Yutaka Okada
Publikováno v:
Oncology. 95:251-256
Purpose: The purpose of the study was to evaluate the site of paronychia in patients with non-small cell lung cancer harboring an epidermal growth factor receptor (EGFR) gene activating mutation who were treated with EGFR tyrosine kinase inhibitors (
Autor:
Naofumi Hara, Chihiro Ando, Katsuyuki Kiura, Atsuko Hirabae, Eiki Ichihara, Takahiro Umeno, Yoshinobu Maeda, Takamasa Nakasuka, Yoshitaka Iwamoto
Publikováno v:
Japanese Journal of Clinical Oncology. 49:786-788
Exon 18 delE709_T710insD is an extremely rare mutation in epidermal growth factor receptor (EGFR) in non-small-cell lung cancer (NSCLC); the efficacy of EGFR tyrosine kinase inhibitors against this mutation remains unclear. In this case report, we re
Autor:
Vincent Haddad, Jie Wang, You Lu, Yuri Rukazenkov, Xiaojin Shi, Jean-Charles Soria, Sang-We Kim, Yi-Long Wu, Tony Mok, Santiago Ponce, Kenneth S Thress, Shinji Atagi, Jin-Ji Yang, James Chih-Hsin Yang, Myung-Ju Ahn, Kazuhiko Nakagawa
Publikováno v:
Journal of Clinical Oncology. 35:4027-4034
Purpose The Iressa Mutation-Positive Multicentre Treatment Beyond ProgRESsion Study (IMPRESS) compared the continuation of gefitinib plus chemotherapy with placebo plus chemotherapy in patients with epidermal growth factor receptor ( EGFR) mutation
Autor:
William Pao, Matthias Freiwald, Vincent A. Miller, Scott N. Gettinger, Leora Horn, Vikram K. Chand, Egbert F. Smit, Bushi Wang, Harry J.M. Groen, D. Ross Camidge, Yelena Y. Janjigian, Jean Fan
Publikováno v:
Horn, L, Gettinger, S, Camidge, D R, Smit, E F, Janjigian, Y Y, Miller, V A, Pao, W, Freiwald, M, Fan, J, Wang, B, Chand, V K & Groen, H J M 2017, ' Continued use of afatinib with the addition of cetuximab after progression on afatinib in patients with EGFR mutation-positive non-small-cell lung cancer and acquired resistance to gefitinib or erlotinib ', Lung Cancer, vol. 113, pp. 51-58 . https://doi.org/10.1016/j.lungcan.2017.08.014
Lung Cancer, 113, 51-58. ELSEVIER IRELAND LTD
Lung Cancer, 113, 51-58. Elsevier Ireland Ltd
Lung Cancer, 113, 51-58. ELSEVIER IRELAND LTD
Lung Cancer, 113, 51-58. Elsevier Ireland Ltd
Objectives In a phase Ib trial, afatinib plus cetuximab demonstrated promising clinical activity (objective response rate [ORR]: 29%; median progression-free survival [PFS]: 4.7 months) in patients with epidermal growth factor receptor (EGFR) mutatio